Articles tagged with Blood Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers evaluate an integrated NGS system, delivering accurate diagnoses in under 24 hours and expanding targeted treatments available to patients with myeloid neoplasms. The assay identified 80-92% of genetic variants, demonstrating promising results for accelerating precision therapies.
Pusan National University researchers have identified a novel gene, SURF4, that regulates cell death and differentiation in acute myeloid leukemia (AML). The study found that suppressing SURF4 expression increases cell differentiation, cell death, and accumulation of ROS, leading to arrested tumor growth in mice.
Researchers found that female patients with diffuse large B-cell lymphoma treated in the afternoon had reduced mortality rates and cancer recurrence compared to those treated in the morning. The study suggests that timing chemotherapy delivery according to an individual's circadian clock may improve treatment outcomes.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
A new study standardizes the use of optical genome mapping (OGM) for patients with blood cancers, demonstrating its potential as a frontline test for diagnosing hematologic malignancies. OGM outperforms existing tests in detecting cancer-causing gene variants and identifying additional information that can improve patient outcomes.
Researchers at the University of Bergen have developed a method to predict cancer patient survival within hours of chemotherapy. By analyzing protein ERK1/2 levels in blood samples, they can identify patients who are responding or not responding to treatment, enabling early intervention.
Researchers at WashU Medicine identified a key transition point in the shift from chronic to aggressive leukemia, where blocking a molecule called DUSP6 prevents disease progression. Inhibiting this molecule also reduces inflammation in models of the disease.
A new software developed by researchers at Cold Spring Harbor Laboratory can accurately infers continental ancestry from tumor DNA and RNA. This technology has the potential to lead to more targeted and personalized cancer treatments by identifying genetic connections between cancer and race or ethnicity.
The study found that COVID-19 vaccination in patients with blood cancer activates a strong T cell response, providing protection against serious illness. Patients who form antibodies tend to produce high-quality antibodies capable of neutralizing different SARS-CoV-2 variants.
Researchers found that using tixagevimab-cilgavimab in blood cancer patients prevented moderate and severe COVID cases. The antibody provided protection but did not entirely prevent infection, highlighting the importance of additional safety measures.
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.
A unique clinical trial has achieved a remarkable 97% induction survival rate in patients with acute promyelocytic leukemia (APL) by providing a simplified treatment regimen and 24/7 support from APL experts. This collaborative care model, known as EA9131, significantly reduced early deaths and improved overall survival rates.
Modakafusp alfa has shown significant potential in combating multiple myeloma with 43% of patients experiencing a partial response. The treatment targets interferon in cells expressing CD38, a marker present on myeloma cells and immune cells.
Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.
A new treatment protocol has been shown to significantly reduce the risk of aggressive childhood leukemia returning after chemotherapy. The ALL-11 protocol, which includes an extra year of maintenance chemotherapy for children with specific genetic mutations, has improved five-year survival rates and quality of life for these patients....
Researchers have demonstrated successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous treatment. The novel fourth-generation CAR T therapy, huCART19-IL18, showed safe and potent antitumor efficacy in a Phase I clinical trial.
A Mount Sinai study found that certain inflammatory markers can predict which patients are more likely to respond to COVID-19 immunotherapies. The researchers identified a subtype of COVID-19 patients with hyperinflammation who could benefit from pacritinib, an anti-cancer drug.
Researchers have characterized the functional significance of DDX41 in molecular processes underlying cancer. The study reveals that DDX41 serves crucial functions in transcriptional processes, RNA splicing, and genomic integrity maintenance, which may hold significance in treating hematopoietic malignancies.
Scientists have developed a new technology that captures the key features of human bone marrow, allowing for the screening of multiple anti-cancer drugs and testing personalized treatments. The 'bone marrows in a dish' can support the survival of cells from patients with blood malignancies
USCF researchers have developed a new approach called CAR Pooling to compare different re-engineered T cells with varying molecular features. The screen revealed new and surprising receptors that make these therapeutic cells more powerful, promising a better treatment for blood cancers.
Researchers at UVA Cancer Center have identified interleukin-1 as a crucial contributor to the development of myelofibrosis, a potentially deadly bone marrow cancer. Targeting this cytokine could prevent myelofibrosis from progressing and spare bone marrow scarring.
Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.
Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.
Scientists have discovered that leukemia cells can change their DNA read-out to evade treatment, making them harder to treat. The study identified key genetic changes that allow cancer cells to survive and relapse.
Researchers found that liquid biopsies can detect clonal haematopoiesis, a condition placing patients at higher risk of developing myelodysplastic syndrome or acute myeloid leukaemia. The study suggests that these patients should be referred for further evaluation to uncover actual risk and identify potential diagnostic pathways.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.
Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.
Researchers at Universidad de Navarra identified a biomarker that predicts CAR T cell therapeutic capacity, which could improve treatment outcomes for patients. The study found that high CAR density in CAR T cells is associated with a worse clinical response in hematological tumors.
Researchers at the University of South Australia are using new technologies to speed up blood cancer diagnosis and treatment. The project aims to identify genetic variants that cause cancer, enabling clinicians to provide targeted treatments and improve patient management.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Researchers are studying the interaction between obesity and nitric oxide synthase in triple-negative breast cancer, aiming to develop a new treatment strategy. Another team is investigating the role of NHE6 protein in multiple myeloma resistance to daratumumab treatment, with the goal of improving therapy outcomes for patients.
Researchers have discovered how a common blood stem cell mutation, DNMT3A R882, alters gene activity and produces abnormal blood cells that increase cancer risk. The study found that the mutant cells produce more red blood cells and platelets, leading to higher cardiovascular disease risks.
A new study of over half a million people with type 2 diabetes found that smoking and low physical activity significantly increase the risk of premature death. Individuals with type 2 diabetes who develop cancer are more likely to die in seven years if they are smokers or physically inactive.
A study of NASA astronauts found DNA mutations associated with spaceflight, increasing the risk of cardiovascular disease and blood cancer. Regular screening is recommended to monitor astronaut health.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
A 3-dose Moderna COVID-19 vaccination schedule significantly improved SARS-CoV-2 antibody concentrations in immunocompromised patients. This improvement was comparable to those obtained by healthy individuals after the standard two-dose Moderna vaccination schedule.
A new scale called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale was found to be more effective at predicting frailty than conventional methods. The scale identifies high-risk medications linked to falls and fatigue, allowing oncology teams to deprescribe them and improve patients' overall health.
Researchers have constructed a comprehensive map of CLL genetic changes, providing a better understanding of the complex malignancy. The study identifies key genes and subtypes with distinct prognoses, paving the way for more accurate diagnoses and personalized treatments.
Researchers developed a method to produce generic CAR T cells from induced pluripotent stem cells (iPS cells), which could be produced at scale for multiple patients. The new cells showed enhanced anti-tumor activity and comparable efficacy to current clinical-grade cells.
A study found that a majority of online pharmacies selling imatinib, a chronic myeloid leukemia therapy, are uncertified and operate unsafely. Patients may face risks of nonadherence, treatment failures, and adverse events if they use these pharmacies.
Researchers used Guardant NGS to analyze nearly 17,000 lung cancer samples and found MET amplification in 1.2% of cases, with 20.8% having overlapping oncogenic drivers. The study suggests that high gene copy numbers and smaller amplified regions can be used to enrich for the true MET-sensitive population.
Researchers at Stanford University developed a custom molecule sBCMA-Fc V3 that inhibits the growth of both multiple myeloma and diffuse large B cell lymphoma in mice. The molecules were found to be nontoxic in monkeys, suggesting they could be used to treat humans with these deadly diseases.
A new study from Tel Aviv University found that CRISPR therapeutics can lead to a significant loss of genetic material in treated cells, potentially destabilizing the genome and promoting cancer. The researchers detected up to 10% of cells with lost chromosomes, highlighting the need for extra care when using this technology.
Researchers at Max Delbrück Center for Molecular Medicine found that silencing the EBAG9 gene in CAR T cells increases their effectiveness and reduces side effects. This breakthrough could lead to a new therapy approach for blood cancer patients.
A recent study published in CANCER found that adults with hematologic malignancies mounted immune responses after a COVID-19 booster dose, with 56% of nonresponders producing antibodies. However, the initial vaccine showed limited effectiveness, with only 48% of patients developing detectable antibodies.
Researchers have developed an app to help doctors identify patients with chronic lymphocytic leukemia (CLL) at risk of developing infections, allowing for earlier treatment. The app uses blood test results and genetic data to predict patient risk, improving treatment outcomes and reducing pressure on the healthcare system.
A novel liquid biopsy test can accurately detect cancer DNA in the blood of patients with metastatic breast cancer within five hours, potentially helping oncologists determine if treatments are working. The test's diagnostic accuracy is 85%, correctly detecting cancer 83% of the time and ruling out cancer 92% of the time.
Researchers identified a three-gene signature in multiple myeloma tumors that predicts a positive response to selinexor-based therapy. The discovery could improve patient selection for targeted agents and expand the use of the drug into patients who haven't failed other therapies.
A new study published in Blood Advances reveals significant disparities in end-of-life care for individuals with hematologic malignancies living in rural areas versus metropolitan regions. Rural residents are less likely to receive hospice care, instead often dying in nursing facilities or at home without palliative care.
A groundbreaking study using cellular barcoding in mice reveals that blood cells originate from two independent sources: hematopoietic stem cells and embryonic multipotent progenitor cells. These findings have significant implications for understanding blood cancers, bone marrow transplant, and the aging immune system.
Researchers have discovered a new treatment that combines CAR-T cell therapy with interleukin-7 to enhance its effectiveness in treating blood cancers. The treatment results in significantly increased anti-tumor activity, improved survival rates, and reduced tumor growth in mice.
A new study found that adult survivors of childhood cancer are 80% more likely to be undertreated for cardiovascular risk factors, including hypertension, diabetes, and high cholesterol. The study highlights the need for increased awareness among healthcare professionals and improved health management strategies for cancer survivors.
A new study found that patients with multiple myeloma who received a three-drug combination therapy had improved progression-free survival if they underwent an autologous stem cell transplant soon after treatment. The use of maintenance lenalidomide also conferred substantial clinical benefit.
Researchers discovered that leukemia-initiating cells in MLL-rearranged B-ALL can switch between two metabolic states, which makes them difficult to target. Targeting the quiet, stem cell-like state curbs the leukemia by forcing the cells back to an active proliferation state.
A new study published in Blood Advances found that virtual frailty assessments are both safe and feasible when conducted virtually. The study evaluated 185 patients with blood cancers who completed a virtual assessment, finding that 81.1% successfully completed the test without falls or safety events.
Researchers found that hypomethylating agents can activate the SALL4 oncogene in patients with myelodysplastic syndrome, resulting in poor survival outcomes. Early intervention targeting SALL4 pathways may improve treatment and patient outcomes.
A large-scale study has found that men with prostate cancer have a 50% higher risk of developing serious and potentially fatal blood clots during the five years after their diagnosis. This increased risk is significant because venous thromboembolism (VTE) is a leading cause of death among people with cancer.
A population-scale study found COVID-19 vaccination is effective in most cancer patients but offers lower protection and wanes quickly. Vaccine effectiveness was lower (65.5%) in cancer patients compared to the general population (69.8%), with higher hospitalization and death risks despite vaccination.
A study found that patients with IgD multiple myeloma have a worse prognosis than other types, with higher mortality rates and more kidney damage. The rare blood cancer produces excessive light chains that can damage the kidneys if left untreated.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.